The Spectrum of Extra-intestinal Manifestation of Crohn's Disease

Laraib Jumani¹, Deepak Kataria², Muhammad Umer Ahmed³, Mir Ali Asghar Shah⁴, Kunal Raja², Faizan Shaukat⁵

1. Internal Medicine, Pakistan Institute of Medical Sciences, Islamabad, PAK 2. Internal Medicine, Shaheed Mohtarma Benazir Bhutto Medical University, Larkana, PAK 3. Internal Medicine, Ziauddin University, Karachi, PAK 4. Internal Medicine, Jinnah Postgraduate Medical Center, Karachi, PAK 5. Internal Medicine, Jinnah Post Graduate Medical Center, Karachi, PAK

Corresponding author: Faizan Shaukat, faizan.shaukat89@gmail.com

Abstract

Introduction

Extra-intestinal manifestations (EIM) play an important role in the mortality, morbidity, and quality of life in patients with Crohn's disease (CD). Understanding the prevalence and clinical course of these manifestations is important to understand and manage CD.

Materials and methods

The hospital records of 103 patients diagnosed with CD between July 2016 and December 2019 at a tertiary care hospital in Pakistan were reviewed retrospectively. Baseline demographic and clinical characteristics including sex, age, follow-up duration, CD phenotype at diagnosis, clinical features, and course of EIMs were noted. The diagnosis of CD was based on clinical features in combination with endoscopic and radiologic findings. CD phenotype at diagnosis was assessed using the Montreal Classification by the World Congress of Gastroenterology (WCOG).

Results

The mean age at diagnosis of CD was 31 ±8 years. The most common age group as per the Montreal classification at diagnosis was 17-40 years (68.93%). The most common localization of disease was ileocolonic (70.87%), and the most common disease behavior was non-stricturing and non-penetrating (82.52%). In this study, 41 (39.8%) patients had a minimum of one EIM. The most common EIM was anal skin tags (29.12%), while 24 (23.30%) patients had elevated liver function tests (LFTs), three (2.91%) had peripheral arthritis, and 12 (11.65%) had cutaneous manifestations, the most common being erythema nodosum (7.76%). The most common ophthalmological manifestation was anterior uveitis (3.88%).

Conclusions

EIMs are prevalent in CD patients in Pakistan, yet very little is known about them. Further large-scale studies are needed to assess the frequency and impact of EIMs on patients with CD.

Categories: Internal Medicine, Gastroenterology

Keywords: crohn's disease, inflammatory bowel disease, extraintestinal manifestations

Introduction

Crohn's disease (CD) is a chronic, relapsing inflammatory bowel disease (IBD), which is characterized by granulomatous transmural inflammation. It might affect any part of the gastrointestinal tract, but most commonly involves the ileum, colon, or ileocolonic region [1]. The Montreal Classification by the World Congress of Gastroenterology (WCOG) categorizes CD based on factors including age at diagnosis, disease location, and behavior [2]. CD symptoms are non-specific and vary widely as presentation includes general symptoms such as fever, fatigue, and weight loss, accompanied by intestinal symptoms such as abdominal pain and chronic diarrhea due to inflammation of intestinal mucosa [3,4]. Along with intestinal symptoms, CD also involves extra-intestinal manifestations (EIMs) in 6-36% of patients. The most commonly affected organs are the joints, skin, uvea, blood, and hepatobiliary system. The most common form of EIM is arthropathy. The most diverse EIMs are cutaneous manifestations, which may include characteristic findings such as erythema nodosum and pyoderma gangrenosum as well as other non-specific signs such as cellulitis and lichen planus [5]. EIMs contribute significantly to morbidity and mortality in CD [5]. Very little data are available regarding EIMs in IBD in Pakistan. Understanding the prevalence and clinical course of the EIMs in patients with CD will significantly assist physicians in the management of CD.

Materials And Methods

Received 02/05/2020

Review began 02/06/2020

Review ended 02/07/2020

Published 02/10/2020

© Copyright 2020

Jumani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Jumani L, Kataria D, Ahmed M, et al. (February 10, 2020) The Spectrum of Extra-intestinal Manifestation of Crohn's Disease. Cureus 12(2): e6928. DOI 10.7759/cureus.6928

The hospital records of 103 patients diagnosed with CD between July 2016 and December 2019 at a tertiary care hospital in Pakistan were reviewed retrospectively. The following demographic and clinical characteristics were included: sex, age, follow-up duration, CD phenotype at diagnosis, clinical features, and frequency of EMIs. The diagnosis of CD was based on clinical features in combination with endoscopic and radiologic findings. CD phenotype at diagnosis was assessed using the Montreal Classification (Table 1) [2].

The Montreal Classification		
Age at diagnosis, years	A1	<17
	A2	17-40
	A3	>40
Disease location	L1	Terminal ileum
	L2	Colon
	L3	Ileocolonic
	L4	Isolated upper gastrointestinal
Behavior	B1	Non-structuring, non-penetrating
	B2	Structuring
	B3	Penetrating
	P	Perianal disease modifier*

TABLE 1: The Montreal Classification of inflammatory bowel disease

A1, A2, A3: different categories based on age at diagnosis; L1, L2, L3: different categories based on disease location; B1, B2, B3: different categories based on disease behavior

*P is added to modify the B1-B3 classification when concomitant perianal disease is present

Pain, swelling, redness, and tenderness of one or more joints were identified as arthritis. Erythema nodosum was diagnosed when tender, red nodules were present, mainly on the extensor surface of the legs. Skin and eye lesions were identified with the help of dermatologists and ophthalmologists.

Results

In our study, 103 complete records of patients were identified and included; 53 (51.45%) patients were male, and 50(48.55%) were female. The mean age at diagnosis of CD was 31 ±8 years. The most common age group as per the Montreal Classification was 17-40 years at diagnosis (68.93%). The most common localization of disease was the ileocolonic region (70.87%), and the most common disease behavior was non-stricturing, non-penetrating (82.52%) (Table 2).

Patient details as per Montreal Classification			Number of patients (%)
Age at diagnosis, years	A1	<17	23 (22.33%)
	A2	17-40	71 (68.93%)
	A3	>40	9 (8.73%)
Disease Location	L1	Terminal ileum	14 (13.59%)
	L2	Colon	16 (15.53%)
	L3	Ileocolonic	73 (70.87%)
	L4	Isolated upper gastrointestinal	0
Behavior	B1	Non-structuring, non-penetrating	85 (82.52%)
	B2	Structuring	12 (11.65%)
	B3	Penetrating	6 (5.82%)
	P	Perianal disease modifier*	48 (46.6%)

TABLE 2: Patient characteristics in the study based on Montreal Classification

A1, A2, A3: different categories based on age at diagnosis; L1, L2, L3: different categories based on disease location; B1, B2, B3: different categories based on disease behavior

*P is added to modify the B1-B3 classification when concomitant perianal disease is present

The most common EIM observed was anal skin tags (29.12%). Twenty-four (23.30%) patients had elevated liver function tests, while three had peripheral arthritis, and 13 (12.62%) had cutaneous manifestations, the most common being erythema nodosum (7.76%). The most common ophthalmologic manifestation was anterior uveitis (3.88%) (Table 3).

Extra-intestinal manifestations	Number of patients (%)
Anal skin tags	30 (29.12%)
Elevated LFTs	24 (23.30%)
Peripheral arthritis	13 (12.62%)
Erythema nodosum	08 (7.76%)
Pyoderma gangrenous	03 (2.91 %)
Psoriasis	01 (0.97%)
Eczema	01 (0.97%)
Anterior uveitis	04 (3.88%)
Scleritis	03 (2.91%)
Conjunctivitis	03 (2.91%)

TABLE 3: Frequency of extra-intestinal manifestations in study participants

LFT: liver function test

Discussion

In our study, the mean age at diagnosis was 31 ±8 years, with the most common age group being 17-40 years. This is consistent with various studies that state that CD is usually diagnosed in the second or third decade of life [6]. In this study, the disease was most commonly localized in the ileocolonic region (70.87%). It is

important to identify the site of disease as it is associated with complications and future need for surgery. Disease localized in the ileum is more commonly associated with stricturing and fistulizing CD phenotypes [7]. Along with a higher rate of complications, disease localized in the ileum is associated with the need for CD-related surgery including small bowel resection, strictureplasty, and abscess drainage [7]. In this study, 41 (39.8%) patients had a minimum of one EIM. This was comparable to findings from a study conducted in India, which stated a prevalence of 38% EIM in IBD [8]. The prevalence in our study was slightly higher. Lakatos et al. stated that 20-25% of patients with CD had one major EIM [5]. Despite their prevalence, the pathogenesis of EIMs in patients with CD is not completely understood. One of the more accepted theories is that patients' gastrointestinal mucosa can trigger an immune response in extraintestinal sites due to common epitopes in genetically susceptible individuals [9-11].

The most common EIM found in our study was anal skin tags; however, their association with disease activity is still controversial. While there have been reports of anal skin tags being more prominent when CD is active, other studies have disputed this finding [12]. Anal skin tags are painless and can vary from being narrow to broad; they are usually present in multiple numbers. However, they are usually benign and require no intervention [13].

Overall, cutaneous manifestations were reported in 13 patients (12.62%). The most common cutaneous manifestation was erythema nodosum (7.76%). The pathogenesis of erythema nodosum as an EIM of CD can be explained as an abnormal immune response that causes a release of cytokines including tumor necrosis factors and interleukins. These inflammatory signals are directed against common epitopes between intestinal bacteria and skin [8]. The nodules' appearance correlates with intestinal activity; they rarely precede the onset of CD or appear during quiescent phases of the disease. Cutaneous lesions disappear with the treatment of CD [14].

Peripheral arthritis was reported in 13 participants (12.62%), which is low in comparison to a regional study conducted in India, which reported a prevalence of 23% [8]. Peripheral arthropathies occur in 5-20% of patients with IBD and are generally most common in CD [15]. The role of various genetic factors such as class I and II molecules of major histocompatibility complex (HLA) in the pathogenesis of IBD including joint involvement has been studied. In patients with IBD, some HLA alleles are associated with increased risk for the development of certain EIMs [16].

Ocular manifestations were found in 10 (9.70%) patients, compared to 13% in a study by Bandyopadhyay et al. [8]. Ocular EIMs are mostly inflammatory in origin and more prevalent in patients with colonic or ileocolonic involvement [8]. The main ocular manifestations include episcleritis, scleritis, and anterior uveitis, all three of which were found in our study [17].

This is the first study conducted in Pakistan that examines EIMs in CD. Despite the study's small sample size, the most common EIMs were all observed in our cohort. However, the study has its limitations. Firstly, since it was a single-institution study, results should be extrapolated to the general population with caution. Secondly, the retrospective nature of the study meant that the relationship between EIM and disease activity could not be inferred.

The prevalence of EIMs was higher in Pakistan compared to instances found in the literature that examined its prevalence in the west. EIMs can involve many vital organs and systems. The pathogenesis of EIMs, although not fully understood, is related to the complex interaction between an adaptive immune response directed against intestinal and extraintestinal sites as they share common epitopes.

Conclusions

It is estimated that one-third of patients with CD exhibit EIMs. It is important to involve specialists such as dermatologists and ophthalmologists early in the management of organs involved. It is also important to counsel patients about EIMs and their relationship to disease activity. Further large-scale studies are warranted to better understand EIMs in CD.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. NA issued approval NA. This was a retrospective study. Permission was taken from Ghulam Muhammad Mahar Medical Hospital, Sukkur to gain access to data. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr: Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. *Gastroenterology*. 2010, 139:1147-55. [10.1053/j.gastro.2010.06.070](#)
2. Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. *Gut*. 2006, 55:749-53. [10.1136/gut.2005.082909](#)
3. Buda P, Friedman-Gruszczynska J, Siemieńska M, Wieteska-Klimczak A, Ksiazek J: Hypocalcaemic seizures as a manifestation of protein-losing enteropathy in Crohn disease - case report. *Prz Gastroenterol*. 2012, 7:237-41. [10.5114/pg.2012.30509](#)
4. Łodyga M, Eder P, Bartnik W, et al.: Guidelines for the management of Crohn's disease. Recommendations of the Working Group of the Polish National Consultant in Gastroenterology and the Polish Society of Gastroenterology. *Prz Gastroenterol*. 2012, 7:317-38.
5. Lakatos L, Pandur T, David G, Balogh Z, Kuronya P, Tollas A, Lakatos PL: Association of extraintestinal manifestations of inflammatory bowel disease in a province of western Hungary with disease phenotype: results of a 25-year follow-up study. *World J Gastroenterol*. 2003, 9:2300-7. [10.3748/wjg.v9.i10.2300](#)
6. Loftus CG, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton LJ 3rd, Sandborn WJ: Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. *Inflamm Bowel Dis*. 2007, 13:254-61. [10.1002/ibd.20029](#)
7. Bernell O, Lapidus A, Hellers G: Risk factors for surgery and postoperative recurrence in Crohn's disease. *Ann Surg*. 2000, 231:38-45. [10.1097/0000658-200001000-00006](#)
8. Bandyopadhyay D, Bandyopadhyay S, Ghosh P, De A, Bhattacharya A, Dhali GK, Das K: Extraintestinal manifestations in inflammatory bowel disease: prevalence and predictors in Indian patients. *Indian J Gastroenterol*. 2015, 34:387-94. [10.1007/s12664-015-0598-8](#)
9. Bhagat S, Das KM: A shared and unique peptide in the human colon, eye, and joint detected by a monoclonal antibody. *Gastroenterology*. 1994, 107:103-8. [10.1016/0016-5085\(94\)90066-3](#)
10. Das KM, Vecchi M, Sakamaki S: A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. *Gastroenterology*. 1990, 98:464-9. [10.1016/0016-5085\(90\)90839-s](#)
11. Das KM: Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. *Dig Dis Sci*. 1999, 44:1-13. [10.1023/a:1026629528233](#)
12. Bonheur JL, Braunstein J, Korelitz BI, Panagopoulos G: Anal skin tags in inflammatory bowel disease: new observations and a clinical review. *Inflamm Bowel Dis*. 2008, 14:1236-9. [10.1002/ibd.20458](#)
13. Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini AA, Rogler G: Extraintestinal manifestations of inflammatory bowel disease. *Inflamm Bowel Dis*. 2015, 21:1982-992. [10.1097/MIB.0000000000000392](#)
14. Korelitz BI: Anal skin tags: an overlooked indicator of Crohn's disease. *J Clin Gastroenterol*. 2010, 44:151-2. [10.1097/MCG.0b013e3181c21d20](#)
15. Ferreira SDC, de Oliveira BBM, Morsolotto AM, Martinelli ALC, Troncon LEA: Extraintestinal manifestations of inflammatory bowel disease: clinical aspects and pathogenesis. *J Gastroenterol Dig Dis*. 2018, 3:4-11.
16. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JL, Jewell DP: Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. *Lancet*. 1996, 347:1212-7. [10.1016/s0140-6736\(96\)90734-5](#)
17. Taleban S, Li D, Targan SR, et al.: Ocular manifestations in inflammatory bowel disease are associated with other extraintestinal manifestations, gender, and genes implicated in other immune-related traits. *J Crohns Colitis*. 2016, 10:43-9. [10.1093/ecco-jcc/jjv178](#)